ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Demyelinating Diseases Therapeutics Market Research Report 2024
Published Date: July 2024
|
Report Code: QYRE-Auto-11G15745
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Demyelinating Diseases Therapeutics Market Research Report 2023
BUY CHAPTERS

Global Demyelinating Diseases Therapeutics Market Research Report 2024

Code: QYRE-Auto-11G15745
Report
July 2024
Pages:91
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
F Hoffmann La Roche Ltd
Pfizer Inc
GSK
Mylan N.V.
Teva Pharmaceutical Industries Ltd
Sanofi
Novartis
Johnson & Johnson Private Limited
Astrazeneca plc
Sun Pharmaceutical Industries Ltd.
Merck& Co. Inc
Lilly
Amgen Inc
Actelion Pharmaceuticals Ltd

Demyelinating Diseases Therapeutics Market Size

The global Demyelinating Diseases Therapeutics market was valued at US$ 854 million in 2023 and is anticipated to reach US$ 1633 million by 2030, witnessing a CAGR of 9.7% during the forecast period 2024-2030.

Demyelinating Diseases Therapeutics Market

Demyelinating Diseases Therapeutics Market

Demyelinating disease is a kind of nervous system disease, in which the main or initial lesion is demyelination, and the damage of axon, cell body and glia is relatively minor. It can occur in the central nervous system or the peripheral nervous system.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Demyelinating Diseases Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Demyelinating Diseases Therapeutics.

Report Scope

The Demyelinating Diseases Therapeutics market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Demyelinating Diseases Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Demyelinating Diseases Therapeutics manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

Scope of Demyelinating Diseases Therapeutics Market Report

Report Metric Details
Report Name Demyelinating Diseases Therapeutics Market
Accounted market size in 2023 US$ 854 million
Forecasted market size in 2030 US$ 1633 million
CAGR 9.7%
Base Year 2023
Forecasted years 2024 - 2030
Segment by Type
  • Immunomodulators
  • Immunosuppressants
  • Interferons
Segment by Application
  • Hospitals
  • Specialty Clinics
  • Others
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company F. Hoffmann-La Roche Ltd, Pfizer Inc, GSK plc, Mylan N.V, Teva Pharmaceutical Industries Ltd, Sanofi, Novartis AG, Johnson & Johnson Private Limited, AstraZeneca, Sun Pharmaceutical Industries Ltd, Merck & Co., Inc, Lilly, Amgen Inc, Actelion Pharmaceuticals Ltd
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Demyelinating Diseases Therapeutics manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Demyelinating Diseases Therapeutics in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report.

FAQ for this report

How fast is Demyelinating Diseases Therapeutics Market growing?

Ans: The Demyelinating Diseases Therapeutics Market witnessing a CAGR of 9.7% during the forecast period 2024-2030.

What is the Demyelinating Diseases Therapeutics Market size in 2030?

Ans: The Demyelinating Diseases Therapeutics Market size in 2030 will be US$ 1633 million.

Who are the main players in the Demyelinating Diseases Therapeutics Market report?

Ans: The main players in the Demyelinating Diseases Therapeutics Market are F. Hoffmann-La Roche Ltd, Pfizer Inc, GSK plc, Mylan N.V, Teva Pharmaceutical Industries Ltd, Sanofi, Novartis AG, Johnson & Johnson Private Limited, AstraZeneca, Sun Pharmaceutical Industries Ltd, Merck & Co., Inc, Lilly, Amgen Inc, Actelion Pharmaceuticals Ltd

What are the Application segmentation covered in the Demyelinating Diseases Therapeutics Market report?

Ans: The Applications covered in the Demyelinating Diseases Therapeutics Market report are Hospitals, Specialty Clinics, Others

What are the Type segmentation covered in the Demyelinating Diseases Therapeutics Market report?

Ans: The Types covered in the Demyelinating Diseases Therapeutics Market report are Immunomodulators, Immunosuppressants, Interferons

1 Demyelinating Diseases Therapeutics Market Overview
1.1 Product Overview and Scope of Demyelinating Diseases Therapeutics
1.2 Demyelinating Diseases Therapeutics Segment by Type
1.2.1 Global Demyelinating Diseases Therapeutics Market Value Comparison by Type (2024-2030)
1.2.2 Immunomodulators
1.2.3 Immunosuppressants
1.2.4 Interferons
1.3 Demyelinating Diseases Therapeutics Segment by Application
1.3.1 Global Demyelinating Diseases Therapeutics Market Value by Application: (2024-2030)
1.3.2 Hospitals
1.3.3 Specialty Clinics
1.3.4 Others
1.4 Global Demyelinating Diseases Therapeutics Market Size Estimates and Forecasts
1.4.1 Global Demyelinating Diseases Therapeutics Revenue 2019-2030
1.4.2 Global Demyelinating Diseases Therapeutics Sales 2019-2030
1.4.3 Global Demyelinating Diseases Therapeutics Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Demyelinating Diseases Therapeutics Market Competition by Manufacturers
2.1 Global Demyelinating Diseases Therapeutics Sales Market Share by Manufacturers (2019-2024)
2.2 Global Demyelinating Diseases Therapeutics Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Demyelinating Diseases Therapeutics Average Price by Manufacturers (2019-2024)
2.4 Global Demyelinating Diseases Therapeutics Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Demyelinating Diseases Therapeutics, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Demyelinating Diseases Therapeutics, Product Type & Application
2.7 Demyelinating Diseases Therapeutics Market Competitive Situation and Trends
2.7.1 Demyelinating Diseases Therapeutics Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Demyelinating Diseases Therapeutics Players Market Share by Revenue
2.7.3 Global Demyelinating Diseases Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Demyelinating Diseases Therapeutics Retrospective Market Scenario by Region
3.1 Global Demyelinating Diseases Therapeutics Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Demyelinating Diseases Therapeutics Global Demyelinating Diseases Therapeutics Sales by Region: 2019-2030
3.2.1 Global Demyelinating Diseases Therapeutics Sales by Region: 2019-2024
3.2.2 Global Demyelinating Diseases Therapeutics Sales by Region: 2025-2030
3.3 Global Demyelinating Diseases Therapeutics Global Demyelinating Diseases Therapeutics Revenue by Region: 2019-2030
3.3.1 Global Demyelinating Diseases Therapeutics Revenue by Region: 2019-2024
3.3.2 Global Demyelinating Diseases Therapeutics Revenue by Region: 2025-2030
3.4 North America Demyelinating Diseases Therapeutics Market Facts & Figures by Country
3.4.1 North America Demyelinating Diseases Therapeutics Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Demyelinating Diseases Therapeutics Sales by Country (2019-2030)
3.4.3 North America Demyelinating Diseases Therapeutics Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Demyelinating Diseases Therapeutics Market Facts & Figures by Country
3.5.1 Europe Demyelinating Diseases Therapeutics Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Demyelinating Diseases Therapeutics Sales by Country (2019-2030)
3.5.3 Europe Demyelinating Diseases Therapeutics Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Demyelinating Diseases Therapeutics Market Facts & Figures by Country
3.6.1 Asia Pacific Demyelinating Diseases Therapeutics Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Demyelinating Diseases Therapeutics Sales by Country (2019-2030)
3.6.3 Asia Pacific Demyelinating Diseases Therapeutics Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Demyelinating Diseases Therapeutics Market Facts & Figures by Country
3.7.1 Latin America Demyelinating Diseases Therapeutics Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Demyelinating Diseases Therapeutics Sales by Country (2019-2030)
3.7.3 Latin America Demyelinating Diseases Therapeutics Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Demyelinating Diseases Therapeutics Market Facts & Figures by Country
3.8.1 Middle East and Africa Demyelinating Diseases Therapeutics Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Demyelinating Diseases Therapeutics Sales by Country (2019-2030)
3.8.3 Middle East and Africa Demyelinating Diseases Therapeutics Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Demyelinating Diseases Therapeutics Sales by Type (2019-2030)
4.1.1 Global Demyelinating Diseases Therapeutics Sales by Type (2019-2024)
4.1.2 Global Demyelinating Diseases Therapeutics Sales by Type (2025-2030)
4.1.3 Global Demyelinating Diseases Therapeutics Sales Market Share by Type (2019-2030)
4.2 Global Demyelinating Diseases Therapeutics Revenue by Type (2019-2030)
4.2.1 Global Demyelinating Diseases Therapeutics Revenue by Type (2019-2024)
4.2.2 Global Demyelinating Diseases Therapeutics Revenue by Type (2025-2030)
4.2.3 Global Demyelinating Diseases Therapeutics Revenue Market Share by Type (2019-2030)
4.3 Global Demyelinating Diseases Therapeutics Price by Type (2019-2030)
5 Segment by Application
5.1 Global Demyelinating Diseases Therapeutics Sales by Application (2019-2030)
5.1.1 Global Demyelinating Diseases Therapeutics Sales by Application (2019-2024)
5.1.2 Global Demyelinating Diseases Therapeutics Sales by Application (2025-2030)
5.1.3 Global Demyelinating Diseases Therapeutics Sales Market Share by Application (2019-2030)
5.2 Global Demyelinating Diseases Therapeutics Revenue by Application (2019-2030)
5.2.1 Global Demyelinating Diseases Therapeutics Revenue by Application (2019-2024)
5.2.2 Global Demyelinating Diseases Therapeutics Revenue by Application (2025-2030)
5.2.3 Global Demyelinating Diseases Therapeutics Revenue Market Share by Application (2019-2030)
5.3 Global Demyelinating Diseases Therapeutics Price by Application (2019-2030)
6 Key Companies Profiled
6.1 F. Hoffmann-La Roche Ltd
6.1.1 F. Hoffmann-La Roche Ltd Corporation Information
6.1.2 F. Hoffmann-La Roche Ltd Description and Business Overview
6.1.3 F. Hoffmann-La Roche Ltd Demyelinating Diseases Therapeutics Sales, Revenue and Gross Margin (2019-2024)
6.1.4 F. Hoffmann-La Roche Ltd Demyelinating Diseases Therapeutics Product Portfolio
6.1.5 F. Hoffmann-La Roche Ltd Recent Developments/Updates
6.2 Pfizer Inc
6.2.1 Pfizer Inc Corporation Information
6.2.2 Pfizer Inc Description and Business Overview
6.2.3 Pfizer Inc Demyelinating Diseases Therapeutics Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Pfizer Inc Demyelinating Diseases Therapeutics Product Portfolio
6.2.5 Pfizer Inc Recent Developments/Updates
6.3 GSK plc
6.3.1 GSK plc Corporation Information
6.3.2 GSK plc Description and Business Overview
6.3.3 GSK plc Demyelinating Diseases Therapeutics Sales, Revenue and Gross Margin (2019-2024)
6.3.4 GSK plc Demyelinating Diseases Therapeutics Product Portfolio
6.3.5 GSK plc Recent Developments/Updates
6.4 Mylan N.V
6.4.1 Mylan N.V Corporation Information
6.4.2 Mylan N.V Description and Business Overview
6.4.3 Mylan N.V Demyelinating Diseases Therapeutics Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Mylan N.V Demyelinating Diseases Therapeutics Product Portfolio
6.4.5 Mylan N.V Recent Developments/Updates
6.5 Teva Pharmaceutical Industries Ltd
6.5.1 Teva Pharmaceutical Industries Ltd Corporation Information
6.5.2 Teva Pharmaceutical Industries Ltd Description and Business Overview
6.5.3 Teva Pharmaceutical Industries Ltd Demyelinating Diseases Therapeutics Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Teva Pharmaceutical Industries Ltd Demyelinating Diseases Therapeutics Product Portfolio
6.5.5 Teva Pharmaceutical Industries Ltd Recent Developments/Updates
6.6 Sanofi
6.6.1 Sanofi Corporation Information
6.6.2 Sanofi Description and Business Overview
6.6.3 Sanofi Demyelinating Diseases Therapeutics Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Sanofi Demyelinating Diseases Therapeutics Product Portfolio
6.6.5 Sanofi Recent Developments/Updates
6.7 Novartis AG
6.6.1 Novartis AG Corporation Information
6.6.2 Novartis AG Description and Business Overview
6.6.3 Novartis AG Demyelinating Diseases Therapeutics Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Novartis AG Demyelinating Diseases Therapeutics Product Portfolio
6.7.5 Novartis AG Recent Developments/Updates
6.8 Johnson & Johnson Private Limited
6.8.1 Johnson & Johnson Private Limited Corporation Information
6.8.2 Johnson & Johnson Private Limited Description and Business Overview
6.8.3 Johnson & Johnson Private Limited Demyelinating Diseases Therapeutics Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Johnson & Johnson Private Limited Demyelinating Diseases Therapeutics Product Portfolio
6.8.5 Johnson & Johnson Private Limited Recent Developments/Updates
6.9 AstraZeneca
6.9.1 AstraZeneca Corporation Information
6.9.2 AstraZeneca Description and Business Overview
6.9.3 AstraZeneca Demyelinating Diseases Therapeutics Sales, Revenue and Gross Margin (2019-2024)
6.9.4 AstraZeneca Demyelinating Diseases Therapeutics Product Portfolio
6.9.5 AstraZeneca Recent Developments/Updates
6.10 Sun Pharmaceutical Industries Ltd
6.10.1 Sun Pharmaceutical Industries Ltd Corporation Information
6.10.2 Sun Pharmaceutical Industries Ltd Description and Business Overview
6.10.3 Sun Pharmaceutical Industries Ltd Demyelinating Diseases Therapeutics Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Sun Pharmaceutical Industries Ltd Demyelinating Diseases Therapeutics Product Portfolio
6.10.5 Sun Pharmaceutical Industries Ltd Recent Developments/Updates
6.11 Merck & Co., Inc
6.11.1 Merck & Co., Inc Corporation Information
6.11.2 Merck & Co., Inc Demyelinating Diseases Therapeutics Description and Business Overview
6.11.3 Merck & Co., Inc Demyelinating Diseases Therapeutics Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Merck & Co., Inc Demyelinating Diseases Therapeutics Product Portfolio
6.11.5 Merck & Co., Inc Recent Developments/Updates
6.12 Lilly
6.12.1 Lilly Corporation Information
6.12.2 Lilly Demyelinating Diseases Therapeutics Description and Business Overview
6.12.3 Lilly Demyelinating Diseases Therapeutics Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Lilly Demyelinating Diseases Therapeutics Product Portfolio
6.12.5 Lilly Recent Developments/Updates
6.13 Amgen Inc
6.13.1 Amgen Inc Corporation Information
6.13.2 Amgen Inc Demyelinating Diseases Therapeutics Description and Business Overview
6.13.3 Amgen Inc Demyelinating Diseases Therapeutics Sales, Revenue and Gross Margin (2019-2024)
6.13.4 Amgen Inc Demyelinating Diseases Therapeutics Product Portfolio
6.13.5 Amgen Inc Recent Developments/Updates
6.14 Actelion Pharmaceuticals Ltd
6.14.1 Actelion Pharmaceuticals Ltd Corporation Information
6.14.2 Actelion Pharmaceuticals Ltd Demyelinating Diseases Therapeutics Description and Business Overview
6.14.3 Actelion Pharmaceuticals Ltd Demyelinating Diseases Therapeutics Sales, Revenue and Gross Margin (2019-2024)
6.14.4 Actelion Pharmaceuticals Ltd Demyelinating Diseases Therapeutics Product Portfolio
6.14.5 Actelion Pharmaceuticals Ltd Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Demyelinating Diseases Therapeutics Industry Chain Analysis
7.2 Demyelinating Diseases Therapeutics Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Demyelinating Diseases Therapeutics Production Mode & Process
7.4 Demyelinating Diseases Therapeutics Sales and Marketing
7.4.1 Demyelinating Diseases Therapeutics Sales Channels
7.4.2 Demyelinating Diseases Therapeutics Distributors
7.5 Demyelinating Diseases Therapeutics Customers
8 Demyelinating Diseases Therapeutics Market Dynamics
8.1 Demyelinating Diseases Therapeutics Industry Trends
8.2 Demyelinating Diseases Therapeutics Market Drivers
8.3 Demyelinating Diseases Therapeutics Market Challenges
8.4 Demyelinating Diseases Therapeutics Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
F Hoffmann La Roche Ltd
Pfizer Inc
GSK
Mylan N.V.
Teva Pharmaceutical Industries Ltd
Sanofi
Novartis
Johnson & Johnson Private Limited
Astrazeneca plc
Sun Pharmaceutical Industries Ltd.
Merck& Co. Inc
Lilly
Amgen Inc
Actelion Pharmaceuticals Ltd
List of Tables
    Table 1. Global Demyelinating Diseases Therapeutics Market Value Comparison by Type (2024-2030) & (US$ Million)
    Table 2. Global Demyelinating Diseases Therapeutics Market Value Comparison by Application (2024-2030) & (US$ Million)
    Table 3. Global Demyelinating Diseases Therapeutics Market Competitive Situation by Manufacturers in 2023
    Table 4. Global Demyelinating Diseases Therapeutics Sales (K Units) of Key Manufacturers (2019-2024)
    Table 5. Global Demyelinating Diseases Therapeutics Sales Market Share by Manufacturers (2019-2024)
    Table 6. Global Demyelinating Diseases Therapeutics Revenue (US$ Million) by Manufacturers (2019-2024)
    Table 7. Global Demyelinating Diseases Therapeutics Revenue Share by Manufacturers (2019-2024)
    Table 8. Global Market Demyelinating Diseases Therapeutics Average Price (US$/Unit) of Key Manufacturers (2019-2024)
    Table 9. Global Key Players of Demyelinating Diseases Therapeutics, Industry Ranking, 2022 VS 2023 VS 2024
    Table 10. Global Key Manufacturers of Demyelinating Diseases Therapeutics, Manufacturing Sites & Headquarters
    Table 11. Global Key Manufacturers of Demyelinating Diseases Therapeutics, Product Type & Application
    Table 12. Global Key Manufacturers of Demyelinating Diseases Therapeutics, Date of Enter into This Industry
    Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 14. Global Demyelinating Diseases Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Demyelinating Diseases Therapeutics as of 2023)
    Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
    Table 16. Global Demyelinating Diseases Therapeutics Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
    Table 17. Global Demyelinating Diseases Therapeutics Sales by Region (2019-2024) & (K Units)
    Table 18. Global Demyelinating Diseases Therapeutics Sales Market Share by Region (2019-2024)
    Table 19. Global Demyelinating Diseases Therapeutics Sales by Region (2025-2030) & (K Units)
    Table 20. Global Demyelinating Diseases Therapeutics Sales Market Share by Region (2025-2030)
    Table 21. Global Demyelinating Diseases Therapeutics Revenue by Region (2019-2024) & (US$ Million)
    Table 22. Global Demyelinating Diseases Therapeutics Revenue Market Share by Region (2019-2024)
    Table 23. Global Demyelinating Diseases Therapeutics Revenue by Region (2025-2030) & (US$ Million)
    Table 24. Global Demyelinating Diseases Therapeutics Revenue Market Share by Region (2025-2030)
    Table 25. North America Demyelinating Diseases Therapeutics Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
    Table 26. North America Demyelinating Diseases Therapeutics Sales by Country (2019-2024) & (K Units)
    Table 27. North America Demyelinating Diseases Therapeutics Sales by Country (2025-2030) & (K Units)
    Table 28. North America Demyelinating Diseases Therapeutics Revenue by Country (2019-2024) & (US$ Million)
    Table 29. North America Demyelinating Diseases Therapeutics Revenue by Country (2025-2030) & (US$ Million)
    Table 30. Europe Demyelinating Diseases Therapeutics Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
    Table 31. Europe Demyelinating Diseases Therapeutics Sales by Country (2019-2024) & (K Units)
    Table 32. Europe Demyelinating Diseases Therapeutics Sales by Country (2025-2030) & (K Units)
    Table 33. Europe Demyelinating Diseases Therapeutics Revenue by Country (2019-2024) & (US$ Million)
    Table 34. Europe Demyelinating Diseases Therapeutics Revenue by Country (2025-2030) & (US$ Million)
    Table 35. Asia Pacific Demyelinating Diseases Therapeutics Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
    Table 36. Asia Pacific Demyelinating Diseases Therapeutics Sales by Region (2019-2024) & (K Units)
    Table 37. Asia Pacific Demyelinating Diseases Therapeutics Sales by Region (2025-2030) & (K Units)
    Table 38. Asia Pacific Demyelinating Diseases Therapeutics Revenue by Region (2019-2024) & (US$ Million)
    Table 39. Asia Pacific Demyelinating Diseases Therapeutics Revenue by Region (2025-2030) & (US$ Million)
    Table 40. Latin America Demyelinating Diseases Therapeutics Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
    Table 41. Latin America Demyelinating Diseases Therapeutics Sales by Country (2019-2024) & (K Units)
    Table 42. Latin America Demyelinating Diseases Therapeutics Sales by Country (2025-2030) & (K Units)
    Table 43. Latin America Demyelinating Diseases Therapeutics Revenue by Country (2019-2024) & (US$ Million)
    Table 44. Latin America Demyelinating Diseases Therapeutics Revenue by Country (2025-2030) & (US$ Million)
    Table 45. Middle East & Africa Demyelinating Diseases Therapeutics Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
    Table 46. Middle East & Africa Demyelinating Diseases Therapeutics Sales by Country (2019-2024) & (K Units)
    Table 47. Middle East & Africa Demyelinating Diseases Therapeutics Sales by Country (2025-2030) & (K Units)
    Table 48. Middle East & Africa Demyelinating Diseases Therapeutics Revenue by Country (2019-2024) & (US$ Million)
    Table 49. Middle East & Africa Demyelinating Diseases Therapeutics Revenue by Country (2025-2030) & (US$ Million)
    Table 50. Global Demyelinating Diseases Therapeutics Sales (K Units) by Type (2019-2024)
    Table 51. Global Demyelinating Diseases Therapeutics Sales (K Units) by Type (2025-2030)
    Table 52. Global Demyelinating Diseases Therapeutics Sales Market Share by Type (2019-2024)
    Table 53. Global Demyelinating Diseases Therapeutics Sales Market Share by Type (2025-2030)
    Table 54. Global Demyelinating Diseases Therapeutics Revenue (US$ Million) by Type (2019-2024)
    Table 55. Global Demyelinating Diseases Therapeutics Revenue (US$ Million) by Type (2025-2030)
    Table 56. Global Demyelinating Diseases Therapeutics Revenue Market Share by Type (2019-2024)
    Table 57. Global Demyelinating Diseases Therapeutics Revenue Market Share by Type (2025-2030)
    Table 58. Global Demyelinating Diseases Therapeutics Price (US$/Unit) by Type (2019-2024)
    Table 59. Global Demyelinating Diseases Therapeutics Price (US$/Unit) by Type (2025-2030)
    Table 60. Global Demyelinating Diseases Therapeutics Sales (K Units) by Application (2019-2024)
    Table 61. Global Demyelinating Diseases Therapeutics Sales (K Units) by Application (2025-2030)
    Table 62. Global Demyelinating Diseases Therapeutics Sales Market Share by Application (2019-2024)
    Table 63. Global Demyelinating Diseases Therapeutics Sales Market Share by Application (2025-2030)
    Table 64. Global Demyelinating Diseases Therapeutics Revenue (US$ Million) by Application (2019-2024)
    Table 65. Global Demyelinating Diseases Therapeutics Revenue (US$ Million) by Application (2025-2030)
    Table 66. Global Demyelinating Diseases Therapeutics Revenue Market Share by Application (2019-2024)
    Table 67. Global Demyelinating Diseases Therapeutics Revenue Market Share by Application (2025-2030)
    Table 68. Global Demyelinating Diseases Therapeutics Price (US$/Unit) by Application (2019-2024)
    Table 69. Global Demyelinating Diseases Therapeutics Price (US$/Unit) by Application (2025-2030)
    Table 70. F. Hoffmann-La Roche Ltd Corporation Information
    Table 71. F. Hoffmann-La Roche Ltd Description and Business Overview
    Table 72. F. Hoffmann-La Roche Ltd Demyelinating Diseases Therapeutics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 73. F. Hoffmann-La Roche Ltd Demyelinating Diseases Therapeutics Product
    Table 74. F. Hoffmann-La Roche Ltd Recent Developments/Updates
    Table 75. Pfizer Inc Corporation Information
    Table 76. Pfizer Inc Description and Business Overview
    Table 77. Pfizer Inc Demyelinating Diseases Therapeutics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 78. Pfizer Inc Demyelinating Diseases Therapeutics Product
    Table 79. Pfizer Inc Recent Developments/Updates
    Table 80. GSK plc Corporation Information
    Table 81. GSK plc Description and Business Overview
    Table 82. GSK plc Demyelinating Diseases Therapeutics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 83. GSK plc Demyelinating Diseases Therapeutics Product
    Table 84. GSK plc Recent Developments/Updates
    Table 85. Mylan N.V Corporation Information
    Table 86. Mylan N.V Description and Business Overview
    Table 87. Mylan N.V Demyelinating Diseases Therapeutics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 88. Mylan N.V Demyelinating Diseases Therapeutics Product
    Table 89. Mylan N.V Recent Developments/Updates
    Table 90. Teva Pharmaceutical Industries Ltd Corporation Information
    Table 91. Teva Pharmaceutical Industries Ltd Description and Business Overview
    Table 92. Teva Pharmaceutical Industries Ltd Demyelinating Diseases Therapeutics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 93. Teva Pharmaceutical Industries Ltd Demyelinating Diseases Therapeutics Product
    Table 94. Teva Pharmaceutical Industries Ltd Recent Developments/Updates
    Table 95. Sanofi Corporation Information
    Table 96. Sanofi Description and Business Overview
    Table 97. Sanofi Demyelinating Diseases Therapeutics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 98. Sanofi Demyelinating Diseases Therapeutics Product
    Table 99. Sanofi Recent Developments/Updates
    Table 100. Novartis AG Corporation Information
    Table 101. Novartis AG Description and Business Overview
    Table 102. Novartis AG Demyelinating Diseases Therapeutics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 103. Novartis AG Demyelinating Diseases Therapeutics Product
    Table 104. Novartis AG Recent Developments/Updates
    Table 105. Johnson & Johnson Private Limited Corporation Information
    Table 106. Johnson & Johnson Private Limited Description and Business Overview
    Table 107. Johnson & Johnson Private Limited Demyelinating Diseases Therapeutics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 108. Johnson & Johnson Private Limited Demyelinating Diseases Therapeutics Product
    Table 109. Johnson & Johnson Private Limited Recent Developments/Updates
    Table 110. AstraZeneca Corporation Information
    Table 111. AstraZeneca Description and Business Overview
    Table 112. AstraZeneca Demyelinating Diseases Therapeutics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 113. AstraZeneca Demyelinating Diseases Therapeutics Product
    Table 114. AstraZeneca Recent Developments/Updates
    Table 115. Sun Pharmaceutical Industries Ltd Corporation Information
    Table 116. Sun Pharmaceutical Industries Ltd Description and Business Overview
    Table 117. Sun Pharmaceutical Industries Ltd Demyelinating Diseases Therapeutics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 118. Sun Pharmaceutical Industries Ltd Demyelinating Diseases Therapeutics Product
    Table 119. Sun Pharmaceutical Industries Ltd Recent Developments/Updates
    Table 120. Merck & Co., Inc Corporation Information
    Table 121. Merck & Co., Inc Description and Business Overview
    Table 122. Merck & Co., Inc Demyelinating Diseases Therapeutics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 123. Merck & Co., Inc Demyelinating Diseases Therapeutics Product
    Table 124. Merck & Co., Inc Recent Developments/Updates
    Table 125. Lilly Corporation Information
    Table 126. Lilly Description and Business Overview
    Table 127. Lilly Demyelinating Diseases Therapeutics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 128. Lilly Demyelinating Diseases Therapeutics Product
    Table 129. Lilly Recent Developments/Updates
    Table 130. Amgen Inc Corporation Information
    Table 131. Amgen Inc Description and Business Overview
    Table 132. Amgen Inc Demyelinating Diseases Therapeutics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 133. Amgen Inc Demyelinating Diseases Therapeutics Product
    Table 134. Amgen Inc Recent Developments/Updates
    Table 135. Actelion Pharmaceuticals Ltd Corporation Information
    Table 136. Actelion Pharmaceuticals Ltd Description and Business Overview
    Table 137. Actelion Pharmaceuticals Ltd Demyelinating Diseases Therapeutics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 138. Actelion Pharmaceuticals Ltd Demyelinating Diseases Therapeutics Product
    Table 139. Actelion Pharmaceuticals Ltd Recent Developments/Updates
    Table 140. Key Raw Materials Lists
    Table 141. Raw Materials Key Suppliers Lists
    Table 142. Demyelinating Diseases Therapeutics Distributors List
    Table 143. Demyelinating Diseases Therapeutics Customers List
    Table 144. Demyelinating Diseases Therapeutics Market Trends
    Table 145. Demyelinating Diseases Therapeutics Market Drivers
    Table 146. Demyelinating Diseases Therapeutics Market Challenges
    Table 147. Demyelinating Diseases Therapeutics Market Restraints
    Table 148. Research Programs/Design for This Report
    Table 149. Key Data Information from Secondary Sources
    Table 150. Key Data Information from Primary Sources
List of Figures
    Figure 1. Product Picture of Demyelinating Diseases Therapeutics
    Figure 2. Global Demyelinating Diseases Therapeutics Market Value Comparison by Type (2024-2030) & (US$ Million)
    Figure 3. Global Demyelinating Diseases Therapeutics Market Share by Type in 2023 & 2030
    Figure 4. Immunomodulators Product Picture
    Figure 5. Immunosuppressants Product Picture
    Figure 6. Interferons Product Picture
    Figure 7. Global Demyelinating Diseases Therapeutics Market Value Comparison by Application (2024-2030) & (US$ Million)
    Figure 8. Global Demyelinating Diseases Therapeutics Market Share by Application in 2023 & 2030
    Figure 9. Hospitals
    Figure 10. Specialty Clinics
    Figure 11. Others
    Figure 12. Global Demyelinating Diseases Therapeutics Revenue, (US$ Million), 2019 VS 2023 VS 2030
    Figure 13. Global Demyelinating Diseases Therapeutics Market Size (2019-2030) & (US$ Million)
    Figure 14. Global Demyelinating Diseases Therapeutics Sales (2019-2030) & (K Units)
    Figure 15. Global Demyelinating Diseases Therapeutics Average Price (US$/Unit) & (2019-2030)
    Figure 16. Demyelinating Diseases Therapeutics Report Years Considered
    Figure 17. Demyelinating Diseases Therapeutics Sales Share by Manufacturers in 2023
    Figure 18. Global Demyelinating Diseases Therapeutics Revenue Share by Manufacturers in 2023
    Figure 19. The Global 5 and 10 Largest Demyelinating Diseases Therapeutics Players: Market Share by Revenue in 2023
    Figure 20. Demyelinating Diseases Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023
    Figure 21. Global Demyelinating Diseases Therapeutics Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
    Figure 22. North America Demyelinating Diseases Therapeutics Sales Market Share by Country (2019-2030)
    Figure 23. North America Demyelinating Diseases Therapeutics Revenue Market Share by Country (2019-2030)
    Figure 24. United States Demyelinating Diseases Therapeutics Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 25. Canada Demyelinating Diseases Therapeutics Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 26. Europe Demyelinating Diseases Therapeutics Sales Market Share by Country (2019-2030)
    Figure 27. Europe Demyelinating Diseases Therapeutics Revenue Market Share by Country (2019-2030)
    Figure 28. Germany Demyelinating Diseases Therapeutics Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 29. France Demyelinating Diseases Therapeutics Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 30. U.K. Demyelinating Diseases Therapeutics Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 31. Italy Demyelinating Diseases Therapeutics Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 32. Russia Demyelinating Diseases Therapeutics Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 33. Asia Pacific Demyelinating Diseases Therapeutics Sales Market Share by Region (2019-2030)
    Figure 34. Asia Pacific Demyelinating Diseases Therapeutics Revenue Market Share by Region (2019-2030)
    Figure 35. China Demyelinating Diseases Therapeutics Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 36. Japan Demyelinating Diseases Therapeutics Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 37. South Korea Demyelinating Diseases Therapeutics Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 38. India Demyelinating Diseases Therapeutics Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 39. Australia Demyelinating Diseases Therapeutics Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 40. China Taiwan Demyelinating Diseases Therapeutics Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 41. Southeast Asia Demyelinating Diseases Therapeutics Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 42. Latin America Demyelinating Diseases Therapeutics Sales Market Share by Country (2019-2030)
    Figure 43. Latin America Demyelinating Diseases Therapeutics Revenue Market Share by Country (2019-2030)
    Figure 44. Mexico Demyelinating Diseases Therapeutics Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 45. Brazil Demyelinating Diseases Therapeutics Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 46. Argentina Demyelinating Diseases Therapeutics Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 47. Middle East & Africa Demyelinating Diseases Therapeutics Sales Market Share by Country (2019-2030)
    Figure 48. Middle East & Africa Demyelinating Diseases Therapeutics Revenue Market Share by Country (2019-2030)
    Figure 49. Turkey Demyelinating Diseases Therapeutics Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 50. Saudi Arabia Demyelinating Diseases Therapeutics Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 51. UAE Demyelinating Diseases Therapeutics Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 52. Global Sales Market Share of Demyelinating Diseases Therapeutics by Type (2019-2030)
    Figure 53. Global Revenue Market Share of Demyelinating Diseases Therapeutics by Type (2019-2030)
    Figure 54. Global Demyelinating Diseases Therapeutics Price (US$/Unit) by Type (2019-2030)
    Figure 55. Global Sales Market Share of Demyelinating Diseases Therapeutics by Application (2019-2030)
    Figure 56. Global Revenue Market Share of Demyelinating Diseases Therapeutics by Application (2019-2030)
    Figure 57. Global Demyelinating Diseases Therapeutics Price (US$/Unit) by Application (2019-2030)
    Figure 58. Demyelinating Diseases Therapeutics Value Chain
    Figure 59. Demyelinating Diseases Therapeutics Production Process
    Figure 60. Channels of Distribution (Direct Vs Distribution)
    Figure 61. Distributors Profiles
    Figure 62. Bottom-up and Top-down Approaches for This Report
    Figure 63. Data Triangulation
    Figure 64. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Samsung SD

SIMILAR REPORTS

Multiple Sclerosis Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Multiple Sclerosis Drugs Treatment Market Insights Forecast to 2030
Global Neurologic Disorders Therapeutics Market Insights Forecast to 2030
Global Neurodegenerative Disease Market Insights Forecast to 2030
Rare Neurodegenerative Disease Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Drugs for Central Nervous System Diseases Market Insights Forecast to 2030
Global Parkinson s Disease Therapeutics Market Research Report 2025
Central Nervous System Disorders Therapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Parkinson s Disease Treatment Market Insights Forecast to 2030
Global Devic s Syndrome Neuromyelitis Optica Treatment Market Insights Forecast to 2030
Acute Disseminated Demyelination Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Central Nervous System CNS Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Nervous System Chemicals Market Research Report 2024
Central Nervous System Therapeutic Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Digital Therapeutics for Nervous System Diseases Market Research Report 2024
Global Alzheimer s Disease Treatments Market Research Report 2024
Global Neurodegenerative Disease Treatment Market Research Report 2024
Global Poliomyelitis Therapeutics Market Insights Forecast to 2030
Central Nervous System Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Alzheimer s Disease Therapeutics and Diagnostics Market Insights Forecast to 2030
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions